1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma antagonists and agonists

RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma antagonists and agonists


Retinoic acid-related orphan nuclear receptor gamma (RORgamma) is a hot, but „difficult-to-drug“ target. More than 30 companies are active in drug discovery and development. Technology companies with expertise in discovery of drugs targeting nuclear hormone receptors are preferred partners of Big Pharma and Biotech companies if they have identified novel scaffolds of RORgamma antagonists. More than ten such technology-pharma partnerships have been founded and already lead to first successes. Three RORgamma antagonists (inverse agonists) are already in clinical development and more to follow in 2016 and thereafter. 


The report explains the scientific rationale for discovering antagonists of RORgamma for treatment of autoimmune and inflammatory diseases, but also of agonists of RORgamma for treatment of cancer. Clinical as well as non-clinical data for target validation of RORgamma are provided. Lead and up-side indications for development including the key product profile are discussed. Potential safety concers for novel RORgamma modulators were identified. Drug discovery approaches of technology and pharmaceutical companies are shown regarding strategies in partnering as well as in technologies applied for structure-based drug discovery. Based on the experience in the past, estimates of the required time from start of a discovery program of RORgamma modulators until entry into human studies are calculated. The competitive landscape of RORgamma modulator development and discovery projects is analyzed and the profiles of companies elaborated, separately for unpartnered technology or pharmaceutical companies and for partnerships between technology and pharmaceutical companies.


The report provides an understanding of:



  • The target RORgamma

  • Clinical and non-clinical target validation

  • Clinical lead and up-side indications

  • Drug discovery strategies and technologies

  • Commercial value of drug discovery collaborations

  • R&D timelines from start of screening to first-in-human studies

  • Competitive landscape of RORgamma antagonists

  • Agonists of RORgamma for cancer

  • Profiles of unpartnered technology companies and lead projects

  • R&D Partnerships and their discovery approaches and lead molecules

  • Unpartnered pharmaceutical companies and their programs


Table Of Contents

RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma antagonists and agonists


Table of Contents


1) Introduction


2) Executive Summary


3) Target Background


4) Target validation


• Clinical Success of Anti-IL17 Antibodies


• Non-Clinical Target Validation


• Clinical Lead Indication for RORgamma Antagonists


• Target-related Potential Safety Concerns


5) Drug Discover Approaches and Technologies


• Drug Discovery Collaboration


• Commercial Value of RORgamma Modulator Drug Discovery Collaborations


• RandD Timelines for Discovery of RORgamma Antagonists in Partnership Programs


• Strategies for the Discovery of Nuclear Receptor Ligands


6) Competitive Landscape of RORgamma Modulators


• RORgamma Antagonists for Inflammatory and Autoimmune Diseases


• Agonists of RORgamma for Cancer


7) Corporate Stakeholders


• Unpartnered Technology Companies


• Partnerships


• Unpartnered Pharmaceutical Companies


8) References?


RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma antagonists and agonists



Tables in the report


Table 1: Disease Models Used for Non-Clinical Studies of RORgamma Antagonists

Table 2: Overview of Non-Clinical Studies of RORgamma Antagonists in Psoriasis Models

Table 3: Overview of Non-Clinical Studies of RORgamma Antagonists in Multiple Sclerosis Models

Table 4: Overview of Non-Clinical Studies of RORgamma Antagonists in Arthritis Models

Table 5: Overview of Non-Clinical Studies of RORgamma Antagonists in Inflammatory Bowel Disease and Ulcerative Colitis Models

Table 6: Overview of Non-Clinical Studies of RORgamma Antagonists in Systemic Lupus Erythematosus Models

Table 6: Overview of Partnership Agreements for RORgamma Modulators

Table 7: Special Collaborations for Discovery of RORgamma Antagonists

Table 8: Financial Terms of Partnership Agreements for RORgamma Modulators

Table 9: Randamp;D Timeline for Discovery of RORgamma Antagonists in Partnership Programs

Table 10: Technologies for Discovery of RORgamma Antagonists

Table 11: RORgamma(T) Antagonists / Inverse Agonists in Clinical Development

Table 12: RORgamma(T) Antagonists / Inverse Agonists in pre-IND Studies

Table 13: RORgamma(T) Antagonists / Inverse Agonists in Preclinical Randamp;D

Table 14: RORgamma(T) Antagonists / Inverse Agonists Discovery Programs

Table 15: RORgamma Agonists Discovery andamp; Development Programs

Table 16: Technology and Pharma Companies with RORgamma Modulator Randamp;D

RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma antagonists and agonists



Companies mentioned in the report


4SC Discovery

Advinus Therapeutics

Amgen

Argenta

Arrien Pharmaceuticals

AstraZeneca

Aurigene Discovery Technologies

Biogen

Boehringer Ingelheim

Brickell Biotech

Bristol-Myers Squibb

Celgene

Daiichi Sankyo

Exelixis

Genfit

GlaxoSmithKline

Glenmark Pharmaceuticals

Innovimmune Biotherapeutics

Janssen Biotech

Japan Tobacco

Karo Bio

Lycera

Merck

Nuevolution

ORCA Pharmaceuticals

Orphagen Pharmaceuticals

Pfizer

Phenex Pharmaceuticals

Piramal (andamp; Krish Biotech)

Roche

Takeda Pharmaceutical Co.

Teijin Pharma

Tempero Pharmaceuticals

Visionary Pharmaceuticals

Vitae Pharmaceuticals

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Scleroderma Diagnostics and Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Scleroderma Diagnostics and Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • November 2016
  • by Transparency Market Research

Global Scleroderma Diagnostics and Therapeutics Market: Overview Scleroderma, a very rare autoimmune disorder of the skin, is a term coined from the Greek words “sklerosis,” which means hardness, and ...

Phototherapy Equipment Market by Type, Application, End-user, Geography - Global Forecast to 2021

Phototherapy Equipment Market by Type, Application, End-user, Geography - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global phototherapy equipment market is projected to reach USD 583.4 million by 2021, growing at a CAGR of 4.5% during the forecast period of 2016 to 2021. This market is primarily driven by the huge ...

U.S. In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases Market (Ankylosing Spondylitis, Alopecia Areata, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis, Psoriasis) By Technology Report, 2013 - 2024

U.S. In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases Market (Ankylosing Spondylitis, Alopecia Areata, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis, Psoriasis) By Technology Report, 2013 - 2024

  • $ 4950
  • Industry report
  • November 2016
  • by Grand View Research

The U.S. IVD for autoimmune diseases market was valued at USD 4.0 billion in 2015 and is expected to reach a value of USD 4.74 billion by 2024 .The U.S. Laboratory Developed Test (LDT) for autoimmune diseases ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.